Avid Bioservices Inc (CDMO)

[biopharm]

Chemo to Immunotherapy as Silicon is to Graphene and overall, as we advance through this phase into Immunotherapy, rather late for Big Pharma advancements, the question is why? and I say its because of greed and families that liked to hold onto what they have for as long as possible. No problem with that, but when society is shown there is a better way to treat cancer patients.... all should gravitate towards that new paradigm.

A paradigm shift into cancer immunotherapy will naturally bring changes of power and we could say its partially due to patents and licensing and those whom hold the core patents/licensing that cancer immunotherapy is based will profit and likely profit in a big way.

Will one of those core patents have much to do with PS Targeting?
You know my answer and it is a big YES.

Maybe a good analogy would be silicon based computer chips vs graphene based. Hell, its been all silicon based and all the big money went in that direction for a very long time and maybe things are about to change, because it seems that a paradigm shift is coming in both indications.

--------------------------------------------

A strange sighting search found here as well, and what do you know.... someone posted an obscure link with the words "graphene" and "phosphatidylserine" - about 7-8 lines into the 1st paragraph:

"Graphene, the blood phosphatidylserine side effects red: pathogen-directed therapy quinone-imine, quinone-methide and maybe. phosphatidylserine side effects.."

http://webcache.googleusercontent.com/search?q=cache:muFM_pDynxAJ:wilsonseniorcare.com/phosphatidylserine-side-effects/+&cd=2&hl=en&ct=clnk&gl=us

----------------------------------------

SBU Researchers Develop Groundbreaking New Graphene-Based MRI Contrast Agent

June 7, 2012

...
..
The MRI, the technology for which was invented at Stony Brook University by Professor Paul Lauterbur, is one of the most powerful and central techniques in diagnostic medicine and biomedical research used primarily to render anatomical details for improved diagnosis of many pathologies and diseases. Currently, most MRI procedures use gadolinium-based contrast agents to improve the visibility and definition of disease detection. However, recent studies have shown harmful side effects, such as nephrogenic systemic fibrosis, stemming from the use of this contrast agent in some patients, forcing the Food and Drug Administration (FDA) to place restrictions on the clinical use of gadolinium. Further, most MRI contrast agents are not suitable for extended-residence-intravascular (blood pool), or tissue (organ)-specific imaging, and do not allow molecular imaging.

To address the need for an MRI contrast agent that demonstrates greater effectiveness and lower toxicity, Dr. Sitharaman developed a novel high-performance graphene-based contrast agent that may replace the gadolinium-based agent which is widely used by physicians today. “A graphene-based contrast agent can allow the same clinical MRI performance at substantially lower dosages,” said Dr. Sitharaman. The project is a Wallace H. Coulter Foundation Translational Research Award winner and the recipient of a two-year translational grant to study preclinical safety and efficacy.

http://commcgi.cc.stonybrook.edu/am2/publish/General_University_News_2/SBU_Researchers_Develop_Groundbreaking_New_Graphene-Based_MRI_Contrast_Agent.shtml

--------------------------------------------------

There have been many strange puzzle pieces that we can not see just yet but didn't Alison Stopeck just move over to SBU ? Stony Brook University... maybe coincidence or maybe not. We'll see soon after her publication and she just may know that Bavi works well and has the correct vision of treatment and now likes to work on the correct vision for MRI detection.

Either way, seems like some are going through an awful lot of trouble to show up here to say there is nothing to look at, when in every direction I look I come to the conclusion that PS Targeting is coveted by some that are frustrated they just can't have it. A license to use it can certainly be drawn up or better yet... buyouts much bigger than Roche/Genentech could be drawn up as well and no wonder why Robert Garnick is here and willing to wait it out for a couple speed bumps.